Phocas Financial Corp. Acquires 103,328 Shares of Pediatrix Medical Group, Inc. $MD
Phocas Financial Corp. significantly increased its stake in Pediatrix Medical Group Inc. (NYSE:MD) by 44.5% during the fourth quarter, acquiring an additional 103,328 shares to hold a total of 335,551 shares valued at approximately $7.18 million. Pediatrix Medical Group reported Q4 results with $0.50 EPS, missing consensus, and revenue of $493.77 million, slightly exceeding estimates. Analysts currently have a "Hold" rating on the stock with a consensus price target of $19.80.
MD Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes MD Financials, focusing on its profitability metrics and market position. It highlights MD's gross margin of 100.00%, operating margin of 11.07%, and net margin of 6.82%, alongside a 20.28% Return on Equity. The company, Pediatrix Medical Group Inc., is compared to competitors like ADUS and AHCO, noting its leading market capitalization of $1.76 billion.
Allspring Global Investments Holdings LLC Acquires New Position in Pediatrix Medical Group, Inc. $MD
Allspring Global Investments Holdings LLC significantly increased its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by purchasing 639,400 shares valued at $13.61 million during the fourth quarter. This acquisition represents 0.74% of the company, and institutional ownership remains very high at 97.71%. Despite a consensus "Hold" rating from analysts and mixed quarterly earnings, several other institutional investors also boosted their positions in Pediatrix.
Pediatrix Medical Group, Inc. (NYSE:MD) Given Consensus Recommendation of "Hold" by Analysts
Pediatrix Medical Group, Inc. (NYSE:MD) has received a consensus "Hold" recommendation from seven analysts, with an average 12-month price target of $19.80. Recent financial results showed an EPS of $0.50, missing estimates by $0.03, though revenue of $493.8 million beat expectations. The stock is currently trading around $21.19, with institutional investors holding approximately 97.7% of the shares.
Pediatrix Medical Group, Inc. Experiences Evaluation Revision Amid Mixed Market Indicators
Pediatrix Medical Group, Inc. has revised its evaluation due to changing market conditions, with its stock priced at $20.50 and a 36.48% year-to-date return, outperforming the S&P 500. Technical indicators show a mixed outlook with both bullish and bearish trends across different time frames, though the company has demonstrated resilience in short-term returns. However, longer-term performance over three, five, and ten years indicates challenges compared to the broader market.
Did Pediatrix’s Earnings-Accretive Tennessee MFM Deal Just Shift Pediatrix Medical Group’s (MD) Investment Narrative?
Pediatrix Medical Group (MD) recently acquired Tennessee Maternal-Fetal Medicine, integrating five locations and a ten-provider team, which is expected to be immediately accretive to earnings. This acquisition strengthens Pediatrix’s focus on high-acuity maternal-fetal care and broader regional coverage. The deal aims to enhance growth despite ongoing risks like payer and hospital fee pressures, with new clinical leadership potentially driving better reimbursement terms and more efficient operations.
Assessing Pediatrix Medical Group (MD) Valuation After Mixed Recent Share Price Performance
Pediatrix Medical Group (MD) is attracting investor attention due to mixed recent share price performance, with a 3.27% 1-month gain contrasted by a 6.05% 90-day decline, though its 1-year return is 41.48%. The stock is currently trading at US$20.50, suggesting a 64% intrinsic discount according to Simply Wall St's analysis, which fair values the company at $21.33. This narrative, however, assumes modest revenue growth and shrinking profit margins, prompting investors to consider various factors impacting its future valuation.
JPMorgan Chase Boosts Stake in Pediatrix Medical Group
JPMorgan Chase has increased its stake in Pediatrix Medical Group by 20.5% during the third quarter, signaling confidence in the healthcare provider's future growth. The investment firm now owns 827,075 shares, valued at approximately $13.85 million. This move suggests JPMorgan sees long-term value in Pediatrix Medical Group's specialized healthcare services.
Tudor Investment Corp ET AL Decreases Stake in Pediatrix Medical Group, Inc. $MD
Tudor Investment Corp ET AL significantly reduced its stake in Pediatrix Medical Group (NYSE:MD) by 48.9%, selling 137,553 shares and now holding 143,560 shares, representing about 0.17% of the company. Despite this, institutional investors collectively own 97.71% of Pediatrix. The company currently has a consensus "Hold" rating from analysts with an average price target of $19.80, and it recently reported an EPS miss but topped revenue forecasts in its latest quarter.
Pediatrix Partners to Enhance Maternal Healthcare Services in Tennessee
Pediatrix Medical Group has expanded its maternal healthcare services by partnering with Tennessee Maternal-Fetal Medicine, specializing in high-risk pregnancies across five Greater Nashville locations. This acquisition, completed through a cash transaction, is expected to immediately boost Pediatrix's financial results and strengthen its presence in Tennessee. Pediatrix shares have surged 48.2% in the past year, significantly outperforming the medical services industry.
Pediatrix Ties Up to Provide Better Maternal Care in Tennessee
Pediatrix Medical Group (MD) has partnered with Tennessee Maternal-Fetal Medicine to expand its maternal health services in the Greater Nashville area. This acquisition, which will see the practice rebranded as Maternal-Fetal Medicine Specialists of Tennessee under Pediatrix, is expected to boost patient volumes and revenue. The move aims to strengthen Pediatrix's presence in Tennessee and meet the demand for specialized maternal care.
Pediatrix acquires Tennessee Maternal-Fetal Medicine practice
Pediatrix Medical Group (NYSE: MD) announced the acquisition of Tennessee Maternal-Fetal Medicine, a practice with four board-certified physicians and six advanced practice providers serving five locations in the Greater Nashville area. The acquisition is expected to be immediately accretive to earnings and expands Pediatrix's maternal-fetal medicine specialty services. Dr. Connie Graves, the practice leader, stated that joining Pediatrix would help improve the quality and outcomes of MFM care nationally.
Pediatrix Expands Maternal Health Services in Tennessee in Partnership with Tennessee Maternal-Fetal Medicine
Pediatrix Medical Group has expanded its maternal health services in Middle Tennessee by partnering with Tennessee Maternal-Fetal Medicine. This collaboration will allow the practice, now operating as Maternal-Fetal Medicine Specialists of Tennessee under the Pediatrix banner, to continue providing comprehensive maternal-fetal care at five locations in the greater Nashville area. The acquisition was a cash transaction, expected to be immediately accretive to Pediatrix’s earnings, and strengthens Pediatrix's commitment to advancing maternal-fetal medicine and improving access to specialized care.
If You Invested $1,000 in Pediatrix Medical Group, Inc. (MD)
This article analyzes the historical performance of a $1,000 investment in Pediatrix Medical Group, Inc. (MD) over 1, 5, and 10 years, detailing its returns and annual performance compared to the S&P 500. It also provides an overview of Pediatrix Medical Group, Inc., highlighting its focus on physician-led healthcare services for women, babies, and children, particularly in neonatology and pediatric subspecialties within hospital settings. The article includes key financial metrics and a description of the company's business model and strategic shifts.
Pediatrix Welcomes Two Nationally Renowned Physician Leaders
Pediatrix Medical Group announced the appointment of two highly respected physician leaders: Dr. James Barry as Chief Clinical Quality & Transformation Officer, and Dr. Jochen Profit as Chief Quality Advisor. These additions aim to enhance the organization's commitment to delivering top-tier patient care for women, babies, and children by leveraging their extensive expertise in clinical quality, research, and innovation. The new hires will significantly contribute to advancing clinical knowledge and practice within the field.
Pediatrix Medical Group (NYSE:MD) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?
Pediatrix Medical Group (NYSE:MD) stock price recently crossed above its 200-day moving average, trading at $20.61 with significant volume. Analysts currently hold a "Hold" rating with an average price target of $19.80, which is below the current trading price. The company reported mixed Q4 earnings, missing EPS estimates but exceeding revenue expectations, and institutional investors hold a substantial portion of the company's shares.
MD SEC Filings - Pediatrix Medical Group, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Pediatrix Medical Group (MD) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms (Form 4). It highlights recent filings such as a Q3 2025 earnings release, a director's stock transfer, and the authorization of a $250 million share repurchase program. The platform also offers AI-powered summaries to help investors understand the key points of each disclosure.
Will Rising Earnings Estimates and Growth Scores Change Pediatrix Medical Group's (MD) Narrative?
Pediatrix Medical Group (MD) is seeing revised earnings estimates and strong growth scores, suggesting a positive shift in its investment narrative. Analysts cite a favorable payer mix, higher patient acuity, and strategic acquisitions as drivers for projected 6.9% earnings growth this fiscal year. Despite risks like lower birth rates, the company's strong financial performance and continued buybacks position it well for future investment and capital returns.
Will Rising Earnings Estimates and Growth Scores Change Pediatrix Medical Group's (MD) Narrative?
Pediatrix Medical Group (MD) is seeing increased analyst focus due to rising earnings estimates and strong growth scores, despite potential risks like lower birth rates. The company's investment narrative is supported by its hospital-based services, recent acquisitions, and a projected fair value of $22.67, indicating a 16% upside. However, investors are advised to monitor potential shifts in healthcare subsidies and reimbursement, which could impact future profitability.
Here's why Pediatrix Medical Group (MD) is a strong growth stock
The article identifies Pediatrix Medical Group (MD) as a strong growth stock. It implicitly suggests that the company possesses characteristics or momentum that make it attractive for investors seeking growth opportunities. The content provided is minimal, offering only the title and an indication of its potential as a growth investment.
Here’s Why Pediatrix Medical Group (MD) Stands Out as a Top Growth Stock
This article highlights Pediatrix Medical Group (MD) as a promising growth stock, emphasizing its strong Growth Style Score of A and projected earnings growth. It explains how Zacks Style Scores, combined with the Zacks Rank, help investors identify stocks with high potential. Pediatrix Medical Group's recent earnings estimate revisions and positive average earnings surprise further underscore its attractiveness for investors.
CSM Advisors LLC Grows Position in Pediatrix Medical Group, Inc. $MD
CSM Advisors LLC significantly increased its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 54.7% in the third quarter, now owning 313,675 shares valued at $5.25 million. Other institutional investors like Canada Pension Plan Investment Board and Smartleaf Asset Management LLC also adjusted their holdings. Analysts have provided mixed ratings for Pediatrix Medical Group, with a consensus "Hold" rating and an average target price of $19.80, following the company's recent earnings report which missed consensus EPS estimates but exceeded revenue expectations.
Cinctive Capital Management LP Has $2.73 Million Stock Position in Pediatrix Medical Group, Inc. $MD
Cinctive Capital Management LP significantly reduced its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 79.0% in Q3, now holding 162,769 shares valued at $2.73 million. Other institutional investors have also adjusted their holdings, with some acquiring new stakes or increasing their positions. Pediatrix Medical Group's stock performance, recent earnings, and analyst ratings, including a recent upgrade to "strong-buy" by Jefferies Financial Group, are also detailed.
Jefferies Financial Group Upgrades Pediatrix Medical Group (NYSE:MD) to "Strong-Buy"
Jefferies Financial Group has upgraded Pediatrix Medical Group (NYSE:MD) to a "Strong-Buy" rating, contrasting with the current consensus "Hold" rating from other analysts. The company recently reported an EPS of $0.50, missing estimates slightly, and revenue of $493.77 million, which was above expectations but down year-over-year. Despite the mixed earnings report and other analysts maintaining "Hold" or "Neutral" ratings, Jefferies' upgrade suggests a more optimistic outlook for the stock.
Jefferies Financial Group Inc. Takes $1.06 Million Position in Pediatrix Medical Group, Inc. $MD
Jefferies Financial Group Inc. has acquired a new stake of 63,410 shares, valued at approximately $1.06 million, in Pediatrix Medical Group, Inc. during the third quarter, representing 0.07% of the company. Other institutional investors like Victory Capital Management and American Century Companies Inc. also significantly increased their positions. Despite these investments, analysts currently hold a consensus "Hold" rating for Pediatrix with a target price of $19.80, following recent price target reductions by several firms.
Reasons Investors Remain Committed to Pediatrix Medical Shares
Pediatrix Medical Group, Inc. (MD) maintains investor confidence due to its strong payer mix, increasing patient acuity in neonatology, and strategic acquisitions, positioning it for continued expansion. With promising growth outlooks, including projected earnings increases and attractive valuation metrics, the company holds a Zacks Rank #3 (Hold). Despite potential risks such as declining birth rates and changes to the Affordable Care Act, Pediatrix Medical's disciplined approach is expected to support its long-term growth trajectory alongside top alternatives in the medical sector like Community Health Systems, Biodesix, and The Ensign Group.
Reasons Investors Remain Committed to Pediatrix Medical Shares
Pediatrix Medical Group (MD) is expected to continue its expansion due to a strong payer mix, increased patient acuity in neonatology, and strategic acquisitions. The company shows promising financial projections, including a projected 6.9% increase in EPS for 2026 and robust revenue growth, making it a solid choice for investors despite potential risks like declining birth rates and changes in healthcare subsidies.
WINTON GROUP Ltd Buys 136,820 Shares of Pediatrix Medical Group, Inc. $MD
WINTON GROUP Ltd significantly increased its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 174.8% in Q3, purchasing 136,820 shares to hold a total of 215,096 shares valued at approximately $3.60 million. This move makes WINTON GROUP Ltd own about 0.25% of the company's stock. Despite this institutional confidence, Pediatrix recently missed EPS consensus in its Q4 earnings report, though revenue exceeded estimates, and analysts maintain a "Hold" consensus rating with an average target price of $19.80.
Pediatrix Medical Group, Inc. (NYSE:MD) Given Consensus Recommendation of "Hold" by Analysts
Pediatrix Medical Group, Inc. (NYSE:MD) has received a consensus "Hold" recommendation from analysts, with an average 12-month price target of $19.80. The company reported mixed quarterly results, missing EPS estimates ($0.50 vs. $0.53) but exceeding revenue expectations ($493.77M). Insider selling by CEO Mark Ordan and significant institutional ownership were also noted.
Victory Capital Management Inc. Has $69.11 Million Stock Holdings in Pediatrix Medical Group, Inc. $MD
Victory Capital Management Inc. significantly increased its stake in Pediatrix Medical Group (NYSE:MD) by 30.7% in Q3, now owning 4.13 million shares valued at $69.11 million. Despite a missed EPS target in its last earnings report, analysts maintain a "Hold" rating with an average $19.80 price target. Institutional investors and hedge funds hold a substantial 97.71% of the stock, while the CEO recently sold a portion of his holdings.
Pediatrix Medical Group, Inc. $MD Shares Sold by Segall Bryant & Hamill LLC
Segall Bryant & Hamill LLC significantly reduced its stake in Pediatrix Medical Group (NYSE: MD) by 77.8% in Q3, selling over 500,000 shares. Despite this, institutional ownership remains high at 97.71%, with other major funds like American Century and JPMorgan Chase & Co. increasing their holdings. Analysts maintain a cautious outlook with an average "Hold" rating and a price target of $19.80, following the company's recent EPS miss.
Pediatrix’s Profit Return And Heavy Buybacks Could Be A Game Changer For Pediatrix Medical Group (MD)
Pediatrix Medical Group (MD) reported a return to profitability in 2025 with US$165.39 million in net income and completed significant share repurchase programs, which could impact per-share earnings and financial flexibility. While the company's investment narrative includes projected revenue and earnings growth by 2028, analysts have varying outlooks, with some more optimistic on pricing power and NICU volumes. Investors are encouraged to conduct their own research into the company's financial health and potential warning signs.
JPMorgan Chase & Co. Has $13.85 Million Holdings in Pediatrix Medical Group, Inc. $MD
JPMorgan Chase & Co. has significantly increased its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 20.5%, now holding 827,075 shares valued at $13.85 million. This represents approximately 0.95% of the company, which recently reported Q3 earnings with a slight EPS miss but beat revenue expectations. Institutional ownership of Pediatrix is notably high at 97.71%, while insiders hold 0.90%, following a recent share sale by CEO Mark S. Ordan.
Pediatrix’s Profit Return And Heavy Buybacks Could Be A Game Changer For Pediatrix Medical Group (MD)
Pediatrix Medical Group (MD) recently reported a return to annual profitability in Q4 2025, with net income of US$165.39 million for the full year, a significant improvement from a US$99.07 million loss in 2024. This, coupled with substantial share repurchase programs, including the retirement of over 4 million shares, could positively impact per-share earnings and financial flexibility for investors. However, the company still faces challenges such as year-on-year revenue softness and potential pressures from rising salary and staffing costs.
A Look At Pediatrix Medical Group (MD) Valuation After Recent Share Price Weakness
Pediatrix Medical Group (MD) has seen a recent share price weakness, with a 7% drop over the past month and 17% over three months, despite positive one-year and three-year returns. The stock is currently trading at US$19.85, below a fair value estimate of $22.67, suggesting it is undervalued by approximately 12.4%. Investors are encouraged to review the company's risk and reward profile, considering potential for operational efficiencies and strategic growth against challenges like staff cuts and rising costs.
Pediatrix (NYSE: MD) EVP awarded stock; additional shares held in trust
Pediatrix Medical Group EVP and General Counsel Mary Ann E. Moore was awarded 39,925 shares of company common stock on March 1, 2026, as part of a performance-based program. On the same date, 26,931 shares were withheld to cover tax obligations upon vesting, at a price of $19.85 per share. Following these transactions, Ms. Moore directly holds 149,236 shares, with an additional 52,598 shares held indirectly through a trust.
Pediatrix Medical Group, Inc. Experiences Revision in Stock Evaluation Amid Mixed Financial Performance
Pediatrix Medical Group, Inc. reported mixed financial results for the quarter ending December 2025, with strong operating cash flow and a low debt-equity ratio, but a decline in quarterly net profit. While the company has outperformed the S&P 500 over the past year, its three-year performance lags, highlighting the need to address short-term profitability challenges. The company's financial trend has been adjusted due to these varied results, emphasizing both its strengths in liquidity and capital efficiency, and its weaknesses in maintaining consistent quarterly profits.
MD Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial analysis of Pediatrix Medical Group, Inc. (MD), covering its income statement, balance sheet, cash flow, and key financial ratios. It highlights the company's financial health with scores for profitability, growth, leverage, liquidity, and returns, noting its strong Piotroski F-Score and cash-backed earnings quality for fiscal year 2025.
Pediatrix Medical Group, Inc. (MD) Stock Analysis: Exploring a Promising 8.92% Potential Upside
Pediatrix Medical Group, Inc. (MD) offers a potential 8.92% upside with a target price of $21.50, based on its current stock price of $19.74 and a market capitalization of $1.72 billion. Despite a slight revenue contraction, the company demonstrates strong financial health with a forward P/E ratio of 8.40 and a return on equity of 20.28%. Analyst ratings are mixed but optimistic, with two buy and five hold ratings, and technical indicators suggest the stock might be undervalued despite recent downward momentum.
Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology
Pediatrix Medical Group is hosting its 47th annual NEO: The Conference for Neonatology from Feb. 25-27 in Las Vegas, bringing together experts to discuss advancements in neonatal medicine. The conference highlights the critical need for innovation given the high preterm birth rates in the U.S. and will feature sessions on various topics, including a pre-conference workshop and the induction of Dr. Waldemar Carlo into the Legends of Neonatology Hall of Fame.
Earnings Outlook For Pediatrix Medical Group
Pediatrix Medical Group (NYSE: MD) is set to release its quarterly earnings on February 19, 2026, with analysts forecasting an EPS of $0.52. The company has a history of surpassing EPS estimates, which has positively impacted its stock price. Investors will be looking for strong performance and positive future guidance, especially given the stock's 25.86% increase over the last 52 weeks.
Hillsdale Investment Management Inc. Grows Stock Position in Pediatrix Medical Group, Inc. $MD
Hillsdale Investment Management Inc. increased its stake in Pediatrix Medical Group by 20.1% during the third quarter, bringing its total holdings to 452,200 shares valued at approximately $7.57 million. This move comes as institutional investors now own about 97.71% of the company, despite mixed Q4 2025 results where EPS missed estimates but revenue exceeded them, and the CEO sold a portion of his shares. Analysts currently have a consensus "Hold" rating for Pediatrix Medical Group with an average price target of $20.00.
Pediatrix Medical Group (MD) PT Lowered by Truist Securities | M
Truist Securities has maintained a 'Hold' rating for Pediatrix Medical Group (MD) but lowered its price target from $24.00 to $21.00, representing a 12.50% decrease. This adjustment reflects the analyst's updated outlook on the stock, while the consensus of 6 analysts projects an average target price of $21.83 with an "Outperform" status, yet GuruFocus estimates a potential downside based on its GF Value.
MD Q4 Deep Dive: Pricing and Payer Mix Resilience Offset Volume Weakness
Pediatrix Medical Group (NYSE:MD) reported Q4 CY2025 results with revenue topping expectations but non-GAAP profit missing consensus estimates, leading to a negative market reaction. Despite a year-on-year revenue decline and decreased net patient volumes across all service lines, the company managed to offset the impact through favorable payer mix, improved revenue cycle management, and higher patient acuity, resulting in an increased operating margin. Looking ahead, Pediatrix’s guidance for 2026 assumes flat volumes and stable pricing, with management emphasizing cost controls and operational discipline.
Pediatrix Medical Q4 Earnings Miss Estimates Despite Declining Costs
Pediatrix Medical Group (MD) reported fourth-quarter 2025 adjusted earnings per share of 50 cents, falling short of the Zacks Consensus Estimate by 4.9%, despite a 2% year-over-year decline in the bottom line. Net revenues increased 0.5% year over year to $493.8 million, exceeding estimates. The company's results were negatively impacted by higher variable practice incentive compensation and lower-than-expected same-unit revenues, though these were partially offset by improved collection activity and lower operating expenses.
Pediatrix Medical Group, Inc. (NYSE:MD) Q4 2025 Earnings Call Transcript
Pediatrix Medical Group, Inc. reported strong Q4 and full-year 2025 results, with adjusted EBITDA of $66 million and $276 million respectively, exceeding guidance. The company anticipates 2026 adjusted EBITDA to be between $280 million and $300 million, driven by stable metrics and operational initiatives. Pediatrix also introduced new physician alignment programs and plans for opportunistic growth leveraging its strong balance sheet in core pediatric and obstetric areas, as well as potential M&A.
Truist Securities Adjusts Pediatrix Medical Price Target to $21 From $24, Maintains Hold Rating
Truist Securities has revised its price target for Pediatrix Medical Group (NYSE: MD) shares down to $21 from $24, while keeping a "Hold" rating on the stock. This adjustment follows the company's recent Q4 2025 earnings report. Pediatrix Medical Group is a provider of physician services specializing in newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care.
Pediatrix Medical Group Returns to Full-Year Profitability Following Practice Portfolio Realignment
Pediatrix Medical Group reported a return to full-year profitability in 2025 with a net income of $165.4 million, following a significant restructuring that involved divesting office-based practices to focus on hospital-based neonatology and maternal-fetal medicine. Despite a decline in total revenue due to these divestitures, the company achieved same-unit net revenue growth and improved adjusted EBITDA. The strategic refocus aims for organic growth and selective acquisitions within core specialties, with an outlook for increased Adjusted EBITDA in 2026.
Pediatrix Medical Group (NYSE:MD) Shares Gap Down After Earnings Miss
Pediatrix Medical Group (NYSE:MD) experienced a share price gap down after missing analyst earnings estimates for the quarter, reporting $0.50 EPS against an expected $0.53. Despite revenue slightly exceeding estimates at $493.77 million, it represented a 1.7% year-over-year decrease. The stock opened significantly lower at $18.84 from its previous close of $21.97, reflecting investor reaction to the disappointing earnings announcement.
Earnings call transcript: Pediatrix Medical misses Q4 2025 EPS, stock tumbles
Pediatrix Medical Group reported missing its Q4 2025 EPS forecast by 7.41% ($0.50 vs. $0.54 expected), causing its stock to tumble 14.43% pre-market despite exceeding revenue expectations with $494 million. The company projects 2026 adjusted EBITDA of $280-$300 million and flat revenue around $1.9 billion, while focusing on physician alignment programs, telemedicine, and OB hospital medicine expansion. Risks include potential impacts from ACA subsidy changes and declining operating cash flow.
